The effective delivery of cytotoxica gents to tumor cellsi sakey challenge in anticancer therapy. Multivalent integrinspecific ligands are considered ap romising tool to increaset he binding affinity,s electivity,a nd internalization efficiency of small-moleculed rug conjugates. Herein, we report the synthesis and biological evaluation of am ultimeric conjugate containing the high-affinity integrin a v b 3 binding ligand RAFT-c(RGDfK) 4 ,alysosomally cleavable Val-Cit linker,a nd cryptophycin-55 glycinate, a potent inhibitor of tubulin polymerization. In vitro cytotoxicity assays verifiedthat the multimeric RGD-cryptophycin conjugate displays improved potency compared to the monomeric analogue in integrin a v b 3 overexpressing tumor cell lines,w hile significantly reduced activity was observed in the integrin-negative cell line.
The selective delivery of anticancer agents to tumor cells constitutesapromising strategy for an optimized therapeutic index and increased clinicalb enefit in the treatmento fc ancer. Amongt hese approaches, antibody-drug conjugates (ADCs) employ antibodies that specifically bind to target antigens overexpressed on cancer cells and, thus, confert umor-specificity to highly potent cytotoxic agents. [1] Currently six ADCs (Adcetris, Kadcyla,M ylotarg, Besponsa,P olivy and Lumoxiti)h ave been approved foroncological indications, while numerous compounds arei nd ifferent stages of thec linical development. [2, 3] In contrast to ADCs, small molecule-drugc onjugates (SMDCs) are considered to have greatp otential fori mprovedt issuep enetration anda ccelerated tumora ccumulation, whilen ot beingi mmunogenic and are obtainable by chemical synthesis. [4, 5] The heterodimeric transmembrane glycoprotein integrin a v b 3 has been aw idely exploited target due to its high expression in new tumorb lood vessels but also in many cancert ypes (such as glioblastoma, melanoma, lung, breast, prostate, and ovarian cancer), where it plays ak ey role in many steps of disease progression and metastasis. [6, 7] Av ariety of cyclic peptides and peptidomimetics containing the minimumi ntegrin binding motif Arg-Gly-Asp (RGD) have been investigated as high affine and selective a v b 3 integrin ligands. [8, 9] Many of them have been used as carriers for the tumor selective delivery of cytotoxic payloads and imaging agents. [10] [11] [12] Significant advances to further increaset he selectivity and binding affinity of the RGD ligands towards integrin a v b 3 have been achieved using multivalent systems [13] [14] [15] [16] or by increasing the size of monomeric RGD peptides. [17] In this context, amultimeric system comprising ar egioselectively addressable functionalized template (RAFT)c yclodecapeptides caffold and four copies of the functionalized cyclopentapeptide c(RGDfK), [RAFT-c(RGDfK) 4 ], specificf or integrin a v b 3 ,i sapromising synthetic vehicle for drug delivery and imaging applications. [18] It was shown that the labeled tetrameric compound RAFTc(RGDfK) 4 -Cy5 displays a1 0-foldh igher binding affinity towards isolated integrin a v b 3 compared to the monomeric analogue. Additionally,the multimeric ligand efficientlyinternalizes with the a v b 3 receptor through the clathrin-mediated endocytic pathway. [19] For this reason,t he RAFT-c(RGDfK) 4 demonstrates improved and more specific integrin a v b 3 -targeting and imaging properties fori nv itro applications,a sw ell as for the in vivo detection and treatment of solid tumors,c ompared to the monomeric c(RGDfK) peptide. [14, [20] [21] [22] Previously,R AFT-c(RGDfK) 4 was conjugated to aB ax proapoptotic protein derived peptide across ad isulfide bridge (RAFT-c[RGD] 4 -S-S-depsi-cgg-Poro2D). This conjugate displayed ad ose-dependentt oxicity against Me275a nd Colo829 human melanoma cell lines and inducedt umor growth inhibition in Me275 xenografts. [23] However,t he RAFT-poropeptidec onjugate showed ab iological activity in the micromolar range, and, therefore, higha mounts of the compound were necessary for the treatment. To reduce the dosing and increaset he efficacy, the application of more active agents was envisioned. This is an open access article under the terms of Creative Commons Attribution NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the originalw ork is properly cited, the use is non-commercial and no modifications or adaptations are made.
In recent years, considerable research efforts have been devoted to the development of SMDCs based on cryptophycins, afamily of microtubule targeting agents, that are characterized with outstanding potencya nd retained activity against multidrug-resistant (MDR) cancer cell lines. [24] [25] [26] [27] [28] Remarkably,t he synthetic cryptophycin-55 glycinate (1, Figure 1 ) displays adequate stability, exhibits cytotoxic activity in the subnanomolar range and showsh igh antitumor activity in vivo against MDR tumors. [26, 29] We have previously reported that conjugates of monomeric c(RGDfK) ligandsa nd cryptophycin-55 glycinated isplayh igh potencya gainst the M21a nd M21-L human melanoma cells. [26] However, we aimed to improve the tumort argetingp roperties of RGD-cryptophycinc onjugatesu sing multivalent ligands.
Based on previous results, we focus here on the conjugation of the tetrameric RAFT-c(RGDfK) 4 integrin ligand with the highly active cryptophycin derivative, cryptophycin-55 glycinate, aiming at improved selectivity in integrin a v b 3 targeted drug delivery.T aking advantage of an efficient intracellular drug release, ac leavable linker was incorporatedb etween the ligand and the cytotoxic agent consisting of aP EG5-chain, the protease sensitiveV al-Cit dipeptide, and the para-aminobenzyl- oxycarbonyl (PABC) self-immolativem oiety.C ryptophycinw as conjugated to the enzymatically cleavable Val-Cit dipeptide including the PABC moiety via carbamate bond. An alkyne-functionalized PEG5-linker was introduced to the N-terminus of the linker to allow the reaction with the azido-functionalized monomeric (3)o rt etrameric (4)i ntegrin ligands (Scheme 1). The conjugate 5 containing the monomer RGD ligand was synthesized as previously reported, [26] whereas multimeric RGD compound 4 was achieved using am odular convergents trategy that involves the oxime ligation of aldehyde-RGD and RAFT that displays 4a minooxy groups (see the Supporting Information). [18] The multimeric conjugate 6 was obtained by the copper(I)catalyzed alkyne-azide cycloaddition (CuAAC) between the azido-functionalized RAFT-c(RGDfK) 4 The antiproliferative activity of the conjugates was evaluated using three cell lines expressing different levels of integrin a v b 3 .T he U87 human glioblastoma and M21 human melanoma cells were selected based on their high expression of integrin a v b 3 ,w hile the M21-L human melanoma cell line, as table variant of M21 that specifically lacks the a v subunit, was used as negative control. [30] [31] [32] In af irst set of experiment,c ells were incubated with increasing concentrations from 0.1 to 10 nm of the free drug, RAFT-c(RGDfK) 4 or conjugates 5 and 6 for 72 hours and cell viability wasd etermined by MTS assay (Figure 2, Figure S1 , Supporting Information). The calculated IC 50 values are shown in Table 1 .
As expected, the unconjugated RAFT-c(RGDfK) 4 ligand had no or minimal antiproliferativee ffects,w hile cryptophycin-55 glycinatew as highly active and induced as ignificant cell growth inhibition (Figure 2 ). After exposition to a1 0nm concentration of drug, more than 50 %c ell death was observed in case of U87c ells and more than 75 %f or M21 and M21-L cells. The low nanomolar and subnanomolar IC 50 values of the unconjugated drug underline its high potency (Table 1) . Nevertheless, the U87 showedasix-fold, while the M21-L cell line displayed at hree-fold decreaseds ensitivity to cryptophycin compared to the M21 cell line.
The integrin positive cells U87 and M21 displayed adose-dependent inhibition of cell growth upon treatment with the tetrameric and monomeric RGD-cryptophycin conjugates, both compounds exhibiting IC 50 values in the nanomolar range. In strongc ontrast, incubation of the M21-L cells with conjugates 5 and 6 resultedi nm arginalc ell growth inhibition, similar to that observed for the unconjugated ligand.
In U87 cells, only am inimal difference was found between the activity of both conjugates, the conjugate 6 containing the tetrameric ligand being slightly more activea te ach tested concentration. At the same time, the activity of multivalent conjugate 6 was three-fold higher compared to the monomeric conjugate 5 (IC 50 = 2.53 and 7.65 nm,r espectively) when tested in M21 melanoma cells. Remarkably,the multimeric conjugate 6 showedt he same toxicitya st he free cryptophycin-55 glycinatea tt he highest concentration (10 nm), while monomeric conjugate 5 demonstrated ar educed activity.T his clearly underlines the improved internalization and integrin a v b 3 -targeting properties of the multimeric structure and ensures a greater tumor selectivity.M oreover, significantly reduced activity of conjugates was observed in M21-L cells ensuring greater tumor selectivity,b ut also signifying stability of the conjugates 5 and 6 in cell media.
In as econd set of experiments, M21 and M21-L cells were incubated with increasing doses from 1t o2 5nm of the free cryptophycin-55 glycinate or conjugates 5 and 6 for 72 hours and cell viability was analyzed by MTS assay (see the Supporting Information FigureS2, Ta ble S1, Supporting Information). In agreement with the data presented above,the multimeric conjugate 6 showed approximately three-fold increased activity Finally,c onjugation of the tetravalentR GD-ligand to the antimitotic agent cryptophycin across intracellularly cleavable linker,h as dramatically improved the potencyo ft argeted SMDC based on this ligand, compared to the previously reported RAFT-c[RGD] 4 -S-S-depsi-cgg-Poro2D conjugate. [23] These results underscore the importance of using highly active cytotoxic agentsi nthe context of targeted therapy and show promise for future applicationo ft his payload and its derivatives.
Altogether,t hese resultss uggest that the RGD-containing scaffold is highly effective for the delivery of potent anticancer agents,such as cryptophycin. The tetrameric RGD-cryptophycin conjugate displays impressive potency in vitro in different cell lines expressing a v b 3 integrin, especially in M21 melanoma cells. On the basis of the previous and current results, we were able to confirmt hat the multimeric RAFT-c(RGDfK) 4 enhances the selectivity of c(RGDfK) and improves tumor-targeted drug delivery,p roviding ar ationale for its future therapeutic applications in combination with cytotoxic agents.
